* Immunome Inc IMNM.OQ IMNM.O is expected to report
results on August 3 (estimated).
*
* Refinitiv's mean analyst estimate for Immunome Inc is for
a
loss of 16 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Immunome
Inc is
$8, above its last closing price of $7.16.
This summary was machine generated August 1 at 18:37 GMT. All
figures in US dollars unless otherwise stated